title: Anti-hypoxic and anti-ischemic actions of indeloxazine hydrochloride and its optical isomers: possible involvement of cerebral energy metabolism.
abstract: We evaluated the anti-hypoxic and anti-ischemic actions of indeloxazine hydrochloride ((+/-)-2-[(inden-7-yloxy)methyl]morpholine hydrochloride, YM-08054) in comparison with its optical isomers and several selective monoamine uptake inhibitors in mice. The effects of indeloxazine on both cerebral energy metabolism in normal mice and local cerebral glucose utilization in normal rats were also studied. Indeloxazine and its (-)-isomer, with both serotonin and norepinephrine uptake inhibitory actions, and its (+)-isomer, with a serotonin uptake inhibitory action, prolonged the survival time of mice subjected to nitrogen gas and the gasping duration in decapitated mice. Indeloxazine and its (+)-isomer were approximately 3-10 times more potent than the (-)-isomer with regard to their anti-hypoxic and anti-ischemic activities. Selective norepinephrine uptake inhibitors such as maprotiline and viloxazine, and selective serotonin uptake inhibitors such as citalopram, alaproclate and zimeldine, did not show anti-hypoxic properties. On the other hand, amantadine, a selective dopamine uptake inhibitor, and amitriptyline, a tricyclic antidepressant with anticholinergic properties, significantly shortened the survival time in hypoxic mice. In biochemical studies, increases in brain ATP and glucose levels without affecting lactate level in mice and an elevation in local cerebral glucose utilization in 10 brain regions involving the frontal cortex in rats were observed after administration of indeloxazine. These results suggest that indeloxazine and its optical isomers possess anti-hypoxic and anti-ischemic actions distinct from those of typical monoamine uptake inhibitors, and that these effects of indeloxazine may be due, at least in part, to a facilitation of cerebral energy metabolism.
authors.affiliation: Neuroscience and Gastrointestinal Research Laboratory, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Shimizu-Sasamata
authors.forename: M
authors.initials: M
authors.lastname: Terai
authors.forename: M
authors.initials: M
authors.lastname: Harada
authors.forename: M
authors.initials: M
authors.lastname: Yamamoto
mesh_terms: D000818:Animals; D015306:Biogenic Monoamines / Q000037:antagonists & inhibitors; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D001923:Brain Chemistry; D002545:Brain Ischemia / Q000188:drug therapy*; D004734:Energy Metabolism / Q000187:drug effects; D000860:Hypoxia / Q000188:drug therapy* / Q000401:mortality; D007536:Isomerism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009025:Morpholines / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D015306:Biogenic Monoamines; D009025:Morpholines; C020852:indeloxazine